At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 224 enrolled
Drug / intervention
Tenecteplase +1 moredrug
Likely dose
Tenecteplase 0.25 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Multicenter, Open, End-point Blinded, Stratified Block Randomized, Parallel Positive Controlled Clinical Trial of Tenecteplase in Acute Ischemic Stroke With Large Vessel Occlusion Over Time Window
In Brief
A Phase 2 clinical trial evaluating Tenecteplase and The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy) for Stroke. Completed, enrolled 224 participants across 1 site.
Detailed Summary
To explore the efficacy and safety of tenecteplase for acute ischemic stroke patients (onset time 4.5-24h) of large vessel occlusion using early combined CT/MR imaging outcomes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesChina
CollaboratorsPuer People's Hospital, Shanghai 6th People's Hospital, Hexigten Traditional Chinese and Mongolian Medicine Hospital, Yangpu Hospital, School of Medicine, Tongji University, The First Affiliated Hospital of Shanxi Medical University, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Linyi People's Hospital, Shanghai 10th People's Hospital, Nanshi Hospital of Nanyang, Fudan University, Xuzhou Medical University Affiliated Hospital of Huaian, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, The First Affiliated Hospital of Soochow University, Affiliated Haian People's Hospital of Nantong University, First Affiliated Hospital of Harbin Medical University, the Third Hospital of Mianyang, Zhejiang Province People's Hospital, Shanghai East Hospital, The Central Hospital of Jiaozuo Coal Group, Huizhou Municipal Central Hospital, Zhejiang University, The Second Affiliated Hospital of Chongqing Medical University, Ningbo No. 1 Hospital
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2021
Primary CompletionSep 2023
TodayJul 2026
First PostedAug 18, 2020
Enrollment StartSep 28, 2021
Primary CompletionSep 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.9 years ago
Interventions
Tenecteplasedrug
Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)drug
Best treatment arm